These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
21 results:

  • 1. DNA Methylation Analysis to predict Regression of high-grade anal Intraepithelial Neoplasia in HIV+ men (MARINE): a cohort study protocol.
    Dias Gonçalves Lima F; van der Zee RP; Dick S; van Noesel CJM; Berkhof J; Schim van der Loeff MF; Prins JM; Steenbergen RDM; de Vries HJC
    BMJ Open; 2022 Aug; 12(8):e060301. PubMed ID: 35922105
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Biomarker p16 predicts progression risk of anal low-grade squamous intraepithelial lesions.
    Liu Y; Blakely M; Sigel K; Thin TH; Hui P; Donovan M; Gaisa MM
    AIDS; 2018 Oct; 32(16):2309-2316. PubMed ID: 30005024
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy.
    Foster CC; Lee AY; Furtado LV; Hart J; Alpert L; Xiao SY; Hyman NH; Sharma MR; Liauw SL
    PLoS One; 2018; 13(3):e0194234. PubMed ID: 29522569
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
    Rödel F; Martin D; Helmke C; Balermpas P; Fokas E; Wieland U; Rave-Fränk M; Kitz J; Matthess Y; Raab M; Strebhardt K; Rödel C
    Oncotarget; 2016 Aug; 7(33):53339-53349. PubMed ID: 27462786
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic colorectal cancer.
    Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Roh JK; Ahn JB
    Cancer Res Treat; 2016 Jan; 48(1):208-15. PubMed ID: 25943321
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The prognostic value of HPV status and p16 expression in patients with carcinoma of the anal canal.
    Roldán Urgoiti GB; Gustafson K; Klimowicz AC; Petrillo SK; Magliocco AM; Doll CM
    PLoS One; 2014; 9(10):e108790. PubMed ID: 25271758
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer.
    Meyer JE; Panico VJ; Marconato HM; Sherr DL; Christos P; Pirog EC
    J Gastrointest Cancer; 2013 Dec; 44(4):450-5. PubMed ID: 24014082
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma.
    Valmary-Degano S; Jacquin E; Prétet JL; Monnien F; Girardo B; Arbez-Gindre F; Joly M; Bosset JF; Kantelip B; Mougin C
    Hum Pathol; 2013 Jun; 44(6):992-1002. PubMed ID: 23266444
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
    Dallol A; Al-Maghrabi J; Buhmeida A; Gari MA; Chaudhary AG; Schulten HJ; Abuzenadah AM; Al-Ahwal MS; Sibiany A; Al-Qahtani MH
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2069-75. PubMed ID: 23010642
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Characterization of cdkn2a(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing.
    Bihl MP; Foerster A; Lugli A; Zlobec I
    J Transl Med; 2012 Aug; 10():173. PubMed ID: 22925370
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Interrater agreement of anal cytology.
    Darragh TM; Tokugawa D; Castle PE; Follansbee S; Borgonovo S; LaMere BJ; Schwartz L; Gage JC; Fetterman B; Lorey T; Wentzensen N
    Cancer Cytopathol; 2013 Feb; 121(2):72-8. PubMed ID: 22811048
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MTHFR, MTR, and MTRR polymorphisms in relation to p16ink4a hypermethylation in mucosa of patients with colorectal cancer.
    Wettergren Y; Odin E; Carlsson G; Gustavsson B
    Mol Med; 2010; 16(9-10):425-32. PubMed ID: 20549016
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
    Ogino S; Nosho K; Irahara N; Meyerhardt JA; Baba Y; Shima K; Glickman JN; Ferrone CR; Mino-Kenudson M; Tanaka N; Dranoff G; Giovannucci EL; Fuchs CS
    Clin Cancer Res; 2009 Oct; 15(20):6412-20. PubMed ID: 19825961
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Nosho K; Shima K; Irahara N; Kure S; Firestein R; Baba Y; Toyoda S; Chen L; Hazra A; Giovannucci EL; Fuchs CS; Ogino S
    Mod Pathol; 2009 Jul; 22(7):922-32. PubMed ID: 19430421
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.
    Nosho K; Shima K; Kure S; Irahara N; Baba Y; Chen L; Kirkner GJ; Fuchs CS; Ogino S
    Neoplasia; 2009 Jan; 11(1):87-95. PubMed ID: 19107235
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
    Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
    Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. p16ink4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.
    Wettergren Y; Odin E; Nilsson S; Carlsson G; Gustavsson B
    Mol Med; 2008; 14(7-8):412-21. PubMed ID: 18418463
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.